Mouse MC38 CRC tumour cells were implanted into hPD1/hLAG3 transgenic mice and treated with either of three different concentrations of CB213, the anti-PD1 antibody nivolumab [37], or a negative control Humabody (HEL-MSA). The gene discussed is TPO; the disease is neoplasm.